Ghent Gut Inflammation Group Meeting 2025
15-16 May 2025
Ghent, Belgium
Isobel Whitehead presenting a poster.
At Microbiotica, we are translating clinic-led microbiome science into transformative life-changing medicines.
About Us
Building a clinical-stage biopharmaceutical company supported by leaders in precision microbiome science and medicine, and a strong syndicate of investors.
Pipeline
Advancing our pipeline of clinic-ready defined live biotherapeutic products, with known mechanisms of action, for immuno-oncology and inflammatory bowel disease.
Platform
Leveraging our clinic-led discovery platform to enable precise identification of bacteria linked to patient outcomes and targeting of specific patient populations.
News
- Microbiotica unveils multiple mechanisms by which MB310, in clinical development for the treatment of ulcerative colitis, protects the intestinal barrier 6 May 2025
- Microbiotica reveals novel mechanisms showing how the microbiome can improve immunotherapy response based on MB097, a clinical-stage drug candidate being evaluated in combination with KEYTRUDA® (pembrolizumab) in patients with advanced melanoma 29 April 2025
Events
Microbiotica is a clinic-ready biopharmaceutical company developing a pipeline of orally-delivered live biotherapeutic products (LBPs) composed of highly-defined bacterial strains for therapeutic applications in immuno-oncology (IO) and inflammatory bowel disease (IBD).
